US009410155B2

(12) **United States Patent**
Collard et al.

(10) **Patent No.: US 9,410,155 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO VEGF**

(71) Applicant: **CuRNA, Inc.**, Miami, FL (US)

(72) Inventors: **Joseph Collard**, Delray Beach, FL (US); **Olga Khorkova Sherman**, Tequesta, FL (US)

(73) Assignee: **CuRNA, Inc.**, Miami, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/534,349**

(22) Filed: **Nov. 6, 2014**

(65) **Prior Publication Data**

US 2015/0141494 A1 May 21, 2015

Related U.S. Application Data

(62) Division of application No. 13/132,997, filed as application No. PCT/US2009/066455 on Dec. 2, 2009, now Pat. No. 8,927,511.

(60) Provisional application No. 61/119,957, filed on Dec. 4, 2008.

(51) **Int. Cl.**

C07H 21/04	(2006.01)
C12N 15/113	(2010.01)
A61K 31/712	(2006.01)
C12Q 1/68	(2006.01)

(52) **U.S. Cl.**

CPC ***C12N 15/1136*** (2013.01); ***A61K 31/712*** (2013.01); ***C12Q 1/6816*** (2013.01); ***C12Q 1/6883*** (2013.01); ***C12Q 1/6886*** (2013.01); *C12N 2310/11* (2013.01); *C12N 2310/113* (2013.01); *C12Q 2600/156* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,683,195	A	7/1987	Mullis et al.
4,683,202	A	7/1987	Mullis
4,754,065	A	6/1988	Levenson et al.
4,800,159	A	1/1989	Mullis et al.
5,034,506	A	7/1991	Summerton et al.
5,138,045	A	8/1992	Cook et al.
5,218,105	A	6/1993	Cook et al.
5,288,512	A	2/1994	Seiden
5,288,514	A	2/1994	Ellman
5,319,080	A	6/1994	Leumann
5,393,878	A	2/1995	Leumann
5,432,272	A	7/1995	Benner et al.
5,457,189	A	10/1995	Crooke et al.
5,459,255	A	10/1995	Cook et al.
5,474,796	A	12/1995	Brennan
5,491,084	A	2/1996	Chalfie et al.
5,506,337	A	4/1996	Summerton et al.
5,519,134	A	5/1996	Acevedo et al.
5,525,735	A	6/1996	Gallop et al.
5,539,083	A	7/1996	Cook et al.
5,549,974	A	8/1996	Holmes
5,569,588	A	10/1996	Ashby et al.
5,576,302	A	11/1996	Cook et al.
5,593,853	A	1/1997	Chen et al.
5,605,662	A	2/1997	Heller et al.
5,661,134	A	8/1997	Cook et al.
5,708,161	A	1/1998	Reese
5,736,294	A *	4/1998	Ecker et al. 435/375
5,739,119	A	4/1998	Galli et al.
5,739,311	A	4/1998	Lackey et al.
5,756,710	A	5/1998	Stein et al.
5,849,902	A	12/1998	Arrow et al.
5,891,725	A	4/1999	Soreq et al.
5,902,880	A	5/1999	Thompson
5,908,779	A	6/1999	Carmichael et al.
5,965,721	A	10/1999	Cook et al.
5,985,663	A	11/1999	Bennett et al.
6,005,095	A	12/1999	Capaccioli et al.
6,013,639	A	1/2000	Peyman et al.
6,013,786	A	1/2000	Chen et al.
6,034,233	A	3/2000	Ecker et al.
6,100,090	A	8/2000	Monia et al.
6,140,492	A	10/2000	Morelli et al.
6,147,200	A	11/2000	Manoharan et al.
6,165,712	A	12/2000	Foulkes et al.
6,165,990	A	12/2000	Singh et al.
6,175,409	B1	1/2001	Nielsen et al.
6,221,587	B1	4/2001	Ecker et al.
6,239,265	B1	5/2001	Cook
6,242,589	B1	6/2001	Cook et al.
6,268,490	B1	7/2001	Imanishi et al.
6,303,374	B1	10/2001	Zhang et al.
6,307,040	B1	10/2001	Cook et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2686933	4/2008
EP	335451 A3	3/1988

(Continued)

OTHER PUBLICATIONS

Nikiforov et al. (PCR Methods and Applications 1994: 285-291).*

(Continued)

Primary Examiner — Kimberly Chong

(74) *Attorney, Agent, or Firm* — CuRNA, Inc.; Monte R. Browder

(57) **ABSTRACT**

Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.

12 Claims, 9 Drawing Sheets